# Foghorn Therapeutics Inc. (FHTX) · Edgar & Edgarette company card

> Foghorn Therapeutics (FHTX) grew revenue 36.8% in FY2025 to $31 million, operating margin -279% against a -3.8% median for pharmaceutical preparations, equity -54.8% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1822462 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/FHTX) · [JSON](https://www.pops4.com/boards/company/FHTX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $31M |
| Revenue growth, 1 year | 36.8% |
| Revenue growth per year | 120.0% |
| Operating margin | -279.5% (prior year -454.3%) |
| Net margin | -240.3% |
| Operating cash flow | −$86M |
| Capital spending | $50,000 |
| Free cash flow | −$86M |
| Cash | $81M |
| Long-term debt | — |
| Total assets | $198M |
| Total equity | −$109M |
| Equity ÷ assets | -54.8% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -10.28 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed restructuring or exit costs in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; operating loss: a margin of -279.5% in FY2025; revenue is hard to predict: its 80% range is ±75%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $30.9M (FY2025). Experience: revenue up 36.8% on the year, up 120.0% a year over 4 years; operating margin -279.5%, up from -454.3%. Soundness: equity -54.8% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $14.7M and $102.5M next year (method v4.1: its own 4-year record of growth weighed at 50% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $12.8M to $117.7M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -279.5% against a -3.8% median; growth 36.8% against 13.7%.

Range logged 2026-10-02, receipt f969460368a5c6b8, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 2.05 Restructuring or exit costs: 1, latest 2026-10-01 ([filing](https://www.sec.gov/Archives/edgar/data/1822462/000162828026064102/0001628280-26-064102-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-02-23 ([filing](https://www.sec.gov/Archives/edgar/data/1822462/000162828026010377/0001628280-26-010377-index.htm))

## Recent filings

- 10-Q · filed 2026-11-09 · [filing](https://www.sec.gov/Archives/edgar/data/1822462/000162828026071873/0001628280-26-071873-index.htm)
- 8-K · filed 2026-11-09 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1822462/000162828026071871/0001628280-26-071871-index.htm)
- 8-K · filed 2026-10-01 · 2.05 Costs Associated with Exit or Disposal Activities; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1822462/000162828026064102/0001628280-26-064102-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1822462/000162828026053819/0001628280-26-053819-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1822462/000162828026053817/0001628280-26-053817-index.htm)
- 8-K · filed 2026-06-24 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1822462/000162828026045154/0001628280-26-045154-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001822462.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1822462

## Cite

POPS4, Edgar & Edgarette: Foghorn Therapeutics Inc. (FHTX) company card, from the company's own SEC filings, accessed 2026-11-16, https://www.pops4.com/boards/company/FHTX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

